ESC 2026: Tirzepatide 5mg sustains cardiometabolic benefit with weight maintenance
KOLs interviewed by GlobalData consistently recognized tirzepatide's cardiometabolic value as extending well beyond weight loss alone.
Therapy Area
ESC 2026: Evidence supporting SGLT2 inhibitors and finerenone in heart failure grows
ESC 2026: Aficamten breaks new ground in nonobstructive HCM
ESC 2026: Evolocumab explores new frontiers in CV disease prevention
RevMed’s pancreatic cancer drug breezes through with swift approval
Johnson & Johnson’s multiple myeloma treatment secures EC approval
Intismeran autogene a turning point for cancer vaccines
Updated UK guidance for finerenone introduces new treatment for HF patients
